Table 5 Automated quantification by Definiens image analysis software for CD8+ and PD-L1+ cells on FFPE sections. Differentiated tumor component and immune component analysis for PD-L1 expression by pathologist is also shown
Clinical benefit | Independent-samples Kruskal–Wallis test | ||
|---|---|---|---|
DB | NB | p value | |
Definiens CD8 % marker area | |||
Count | 7 | 13 | 0.492 |
Valid N | 6 | 10 | |
Median | 4.3 | 1.8 | |
Percentile 25 | 2.7 | 0.3 | |
Percentile 75 | 9.5 | 4.9 | |
Definiens pdl1 % marker area | |||
Count | 7 | 13 | 0.299 |
Valid N | 6 | 6 | |
Median | 11.1 | 3.7 | |
Percentile 25 | 1.7 | 0.1 | |
Percentile 75 | 20.1 | 8.0 | |
Pathologist evaluation % PDL1 TC | |||
Count | 7 | 13 | 0.240 |
Valid N | 6 | 12 | |
Median | 17.5 | 0 | |
Percentile 25 | 0 | 0 | |
Percentile 75 | 20.0 | 4.5 | |
Pathologist evaluation % PDL1 TC | |||
Count | 7 | 13 | 0.451 |
Valid N | 6 | 12 | |
Median | 4.5 | 1.0 | |
Percentile 25 | 1.0 | 0 | |
Percentile 75 | 5.0 | 4.0 | |